Clinical trial · Interventional
Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
High Dose Conditioning With Ifosfamide, Carboplatin, and Etoposide With Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This is a rare disease, and enrollment was poor.
Summary
Brief summary (as posted)
This is a pilot study to evaluate the response rates for patients undergoing high dose conditioning chemotherapy using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent Nasopharyngeal Cancer (NPC) in children, adolescents, and young adults.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Nasopharynx Carcinoma | Malignant Nasopharyngeal Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Autologous Stem Cell Transplantation | Procedure | — | UNRESOLVED |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Etoposide phosphate | Drug | Etoposide | ALIAS |
| Ifosfamide | Drug | Ifosfamide | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- High Dose Conditioning
- description
- Single arm - receives high dose Etoposide phosphate, Ifosfamide, and Carboplatin followed by Autologous Stem Cell Transplantation
- interventionNames
- Drug: Etoposide phosphate
- Drug: Carboplatin
- Drug: Ifosfamide
- Procedure: Autologous Stem Cell Transplantation
Primary outcomes (1)
- measure
- Evaluate the Tumor Response
- timeFrame
- 12 months after completion of treatment
- description
- To evaluate the response rates for patients undergoing high dose conditioning using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent NPC in children, adolescents, and young adults.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Years
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * Imaging and tissue diagnosis of recurrent or progressive nasopharyngeal carcinoma * Documentation of previous treatment including conventional chemotherapy and/or radiation therapy as clinically appropriate * Ages 2 to 30 years of age * Negative serum pregnancy test if applicable * Calculated creatinine clearance of greater than 60 mL/minute, serum creatinine of less than 12o micromoles/L, total bilirubin less than 2 mg/dL and aspartate aminotransferase (AST) must be less than twice the upper limit of normal Exclusion Criteria: * Unsuitable candidate for autologous transplantation due to comorbidities or intractable psychosocial issues * Pregnancy * Breast-feeding women
References
Publications (0)
Data not yet available